Kornimate/medical-research-clean huggingface dataset:
emergency bedside ultrasound for pediatric soft tissue infections

Conditions: Abscess

Summary: the purpose of this study is to determine if soft tissue infections in pediatric patients can be more accurately diagnosed (i.e. the presence of a drainable abscess) with the addition of bedside ultrasound to the clinical examination compared to the clinical examination alone.

skin and soft tissue infections, particularly abscesses caused by community-acquired methicillin resistant staphylococcus aureus (ca-mrsa) are a growing public health problem. the treatment of a skin abscess usually requires incision and drainage or needle aspiration. in addition to providing definitive therapy, appropriate drainage can allow for organism identification and antibiotic susceptibility testing should antibiotics be utilized. a skin cellulitis, which is treated with systemic antibiotics and supportive care alone, may be hard to distinguish from an abscess, as both have similar clinical features. therefore, as the presence or absence of purulent material may be difficult to determine, children may undergo an unnecessary drainage procedure. if drainage is avoided, the patient may require a subsequent ed visit if the diagnosis is missed on initial examination. this can lead to worsened clinical outcome, an extra financial burden for the family, and added emotional distress for the patient. bedside emergency ultrasound (eus), which has been used since the mid-1980s is being used in adults to detect fluid collections such as soft tissue abscesses. studies in adult patients have shown that eus adds useful information to the history and physical examination and may even alter physicians' clinical impressions and management of patients. currently, it is not known whether children represent a different population for eus than adults and how eus would perform in the pediatric outpatient setting. with improved diagnosis of soft tissue infections, better epidemiologic data about organism prevalence, improved and more prompt treatment, and more appropriate use of antibiotic therapy can be done. to date, no study exists evaluating its utility specifically for the evaluation of soft tissue infections in pediatric patients. the goal of this study is to evaluate the test characteristics of eus in pediatric patients presenting with evidence of soft tissue infection.

Eligibility criteria:
inclusion criteria: * evidence of at least one of the following: skin elevation, induration, tenderness, fluctuance, or history of purulent drainage from the lesion exclusion criteria: * suspected paronychia or felon * lesion involving the face, perirectal, or vaginal area * surgical wound infection * underlying immunodeficiency * non-soft tissue infectious mass (e.g. lymphadenitis) * suspected non-infectious mass (e.g. hernia, lymph node)

Keywords: bedside emergency ultrasound abscess cellulitis soft tissue infection methicillin resistant staphylococcus aureus (mrsa)
mills manipulation and mulligan prp affect pain, grip strength and function on lateral epicondylitis

Conditions: Lateral Epicondylitis

Summary: the aim of this study is to find the comparative effects of mills manipulation with or without mulligan pain release phenomena on the pain, grip strength, and function in patients with lateral epicondylitis. the results of this study will provide clinicians with valuable insights into the most effective treatment approach for lateral epicondylitis, enabling them to stay up-to-date with the latest practice methods and optimize patient care.


Eligibility criteria:
inclusion criteria: * subjects diagnosed with lateral epicondylitis with positive cozen test * nprs \>3 * both male and female patients * sub-acute lateral epicondylitis \>4weeks-\<3 months * subjects with age range 20-40 year exclusion criteria: * acute lateral epicondylitis * subjects with elbow and around elbow fracture * subjects with ligament injury around elbow joint * any neurological conditions * any open wounds around the area of elbow * hyper-sensitive skin, skin allergies, diagnosed subjects with malignancy, diagnosed subjects skin diseases, diagnosed subjects with systemic illness * traumatic injury to the elbow joint

Keywords: lateral epicondylitis elbow pain tennis elbow mills manipulation mulligan pain release phenomena hand grip strength elbow function nprs prtee hand held dynamometer
a study of neutropenia and anemia management in patients with solid tumors receiving myelotoxic chemotherapy

Conditions: Breast Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer; Small Cell Lung Cancer

Summary: the primary objective was to describe the incidence of febrile neutropenia based on granulocyte-colony stimulating factor (g-csf) use (primary, secondary, treatment, or no usage) in patients receiving myelotoxic chemotherapy.

this is a multi-center international observational study of patients receiving myelotoxic regimens, with an investigator assessed risk of febrile neutropenia ≥ 20%, for the treatment of solid tumors (breast, ovarian and lung). this is an observational study in which patient risk factors were qualitatively (but not quantitatively) assessed, and adherence to g-csf primary prophylaxis was at the discretion of physicians and not mandated by the protocol.

Eligibility criteria:
inclusion criteria: * subjects greater than or equal to 18 years old with breast, ovarian or lung cancer receiving chemotherapy in any schedule, e.g. dose dense or standard chemotherapy. * these subjects must have an investigator assessed risk of febrile neutropenia (fn) ≥20% (based on 2006 european organisation for research and treatment of cancer (eortc) g-csf guidelines exclusion criteria: - subjects with concurrent administration of radiotherapy are not eligible (previous radiotherapy is permitted if terminated at least 2 weeks prior to commencing applicable chemotherapy in this study).
iodine status and characteristics of papillary thyroid cancer

Conditions: Papillary Thyroid Carcinoma

Summary: the effect of iodine on papillary thyroid cancer has been controversial for many years. the investigators designed a cross-sectional study and aimed to explore the relationship between the serum and urine iodine levels and the clinical and molecular characteristics of papillary thyroid cancer.


Eligibility criteria:
inclusion criteria: * age range: 18\~65 years old, gender not limited; * living in the residential area for at least 5 years; * patients diagnosed clinically with thyroid cancer and scheduled for thyroid surgery, with pathological diagnosis of papillary thyroid cancer; * complete clinical data: including general information, relevant laboratory tests, pathological reports, surgical reports, ultrasound reports, etc. exclusion criteria: * pathological diagnosis of other types of thyroid cancer; * diagnosed with other types of cancer; * there are serious comorbidities of the heart, liver, and kidneys;

Keywords: iodine status papillary thyroid carcinoma
observational hemodynamic monitoring during lvad implantation among individuals with advanced heart failure

Conditions: Heart Failure; Circulatory Disorders Postprocedural Complication; Cardiomyopathy, Congestive; Surgery

Summary: the overall objective of this pilot analysis is to characterize the hemodynamic changes that occur during implantation of a left ventricular assist device (lvad) in patients with advanced heart failure - specifically, how right ventricular function is compromised as a result of lvad implantation.


Eligibility criteria:
inclusion criteria: * individuals ≥ 18 years of age with severe heart failure (hf) and who have been approved by the advanced hf selection committee for lvad implantation. exclusion criteria: * patients with pre-existing right ventricular (rv) dysfunction/failure, defined as: 1. imaging evidence of moderate-severe rv dysfunction on echocardiography 2. hemodynamic evidence of rv dysfunction with: * a right-atrial pressure (rap): pulmonary capillary wedge pressure (pcwp) ratio of ≥ 0.67 (note: this index compares pressures on the right \[rap\] and left \[pcwp\] side of the heart; * an rap/pcwp ratio ≥ 0.67 provides hemodynamic evidence of rv dysfunction. 3. clinical evidence of preexisting rv dysfunction, as indicated by significant (3-4+ peripheral edema) and/or elevated jugular venous pressures on clinical examination. 4. patients with end-stage renal disease requiring hemodialysis 5. patients requiring temporary hemodynamic support prior to lvad implantation with temporary lvads, and/or veno-arterial extracorporeal membrane oxygenators ("ecmo"). 6. planned concurrent implantation of right ventricular assist device
study of hepatic glucose production and de novo lipogenesis in patients with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: objectives: i. determine the amount of hepatic glucose production derived from gluconeogenesis and glycogenolysis in the post-absorptive state in patients with cystic fibrosis. ii. determine de novo lipogenesis in relationship to resting energy expenditure in this patient population.

protocol outline: patients undergo an oral glucose tolerance test (ogtt) in which blood is drawn from an iv in the arm 6 times over 3 hours. after the first blood draw, patients receive a beverage containing sugar and write down everything they ate and drank during the 24 hours before study entry. patients also undergo a dual energy x-ray absorptiometry (dexa) scan over 15 minutes. within 2 weeks after the ogtt, patients keep a journal of everything they ate and drank over 3 days. patients are fed a selected meal the following evening and receive saline fluids iv overnight. during the night, patients receive 2 doses of oral doubly labeled water. the next morning, patients receive \[1,2-13c\]acetate iv. a liquid mixed meal (ensure plus) is ingested hourly throughout the day. patients also undergo hood indirect calorimetry over 30 minutes twice to measure resting energy expenditure. all urine is collected.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- diagnosis of cystic fibrosis or normal healthy volunteer; not an endurance-trained athlete no colonization with burkholderia cepacia --prior/concurrent therapy-- endocrine therapy: at least 2 months since prior oral or iv corticosteroids; low-dose inhaled corticosteroids allowed other: short-acting insulin therapy allowed; at least 24 hours since prior long-acting insulin (i.e., neutral protamine hagedorn, or ultalente); at least 4 weeks since prior oral or iv antibiotics; no hospital admissions within the past 6 weeks --patient characteristics-- hepatic: no elevation of sgot or sgpt within the past 3 months other: must be medically stable; diabetes mellitus allowed; weight stable within the past 3 months; not pregnant; no prisoners

Keywords: cardiovascular and respiratory diseases cystic fibrosis genetic diseases and dysmorphic syndromes rare disease
characterization of brachial arterial t-pa release, endothelial function, obesity and inflammation

Conditions: Obesity

Summary: t-pa release is impaired in obese subjects. in order to have a better mechanistic understanding of t-pa release, we will compare t-pa release to flow mediated vasodilation, radial artery tonometry, and other markers of endothelial function and oxidative stress.


Eligibility criteria:
inclusion criteria: 1. adults 18 years and greater 2. healthy exclusion criteria: 1. pvc \< 30 2. hypertensive subjects on ace inhibitors 3. pregnant or nursing mothers 4. diabetic with hba1c \> 7.5 or stigmata of end organ damage (neuropathy, retinopathy, nephropathy, cardiomyopathy) 5. cholesterol \> 30 mg/dl above ncep accepted level based on cardiac risk. 6. triglycerides \> 200 7. previously diagnosed obstructive coronary artery disease, myocardial infarction or left ventricular dysfunction (with or without a history of congestive heart failure) 8. renal insufficiency (creatinine ≥ 1.5 mg/dl) 9. history of cerebrovascular disease 10. any chronic inflammatory disease (rheumatologic, inflammatory bowel disease, etc) 11. uncontrolled stage 2 hypertension (160/100 mmhg), or end organ damage due to hypertension (left ventricular hypertrophy, atrial fibrillation, hematuria, renal insufficiency, prior cerebrovascular disease). 12. angiotensin converting enzyme inhibitor use 13. coagulopathy (inr ≥ 1.5, ptt ≥ 1.5 x control) 14. other chronic medical illnesses at the discretion of the investigators

Keywords: obesity endothelial function fibrinolytic balance baseline
safety and efficacy of unrelated cord blood transplantation for adult patients with hematologic malignancies

Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia; Myelodysplastic Syndrome

Summary: the primary purpose of this study is to evaluate the safety and efficacy of cord blood transplantation for adult patients with hematologic malignancies including refractory acute leukemia. the transplant procedure was determined in detail according to the previously published report showing a high survival, so that the investigators could expect a similar result.

although cord blood is considered as an alternative donor source for allogeneic hematopoietic stem cell transplantation, its procedure has yet to be standardized. recently, a single institute result of cord blood transplantation for adult patients with hematologic malignancies have been reported by takahashi et al (blood 2004:104;3813-3820), in which the survival was significantly better than that of bone marrow transplantation from unrelated donor. the purpose of this study was to reevaluate the safety and efficacy of cord blood transplantation for adult patients with hematologic malignancies using the same transplant procedures in a multi-institutional setting.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome * lack of hla-identical or 1 locus mismatched related donor * age over 20, and under 55 * performance status 0 or 1 * no moderate or sever organ dysfunction (liver, kidney, heart, lungs) * no anti-hla antibody * informed consent was obtained exclusion criteria: * uncontrollable diabetes * uncontrollable hypertension * active infection * tpha, hbs-ag, hcv-ab positive * htlv-i, hiv positive

Keywords: cord blood transplantation myeloablative regimen hematologic malignancies
fast identification of pathogen in the setting of hospital-acquired pneumonia using ion mobility spectrometry

Conditions: Acute Lower Respiratory Tract Infection; Pneumonia

Summary: with this study the investigators want to determine, if a fast identification of germs, causing hospital-acquired infections of the lower respiratory tract, is possible through the use of mcc-ims technology - a method that allows on time detection and identification of very small amounts of substances in gas samples. therefore aspiration samples from the respiratory tracts of ventilated patients, which are suspected to develop such an infection, will be collected, cultivated and analyzed by mcc-ims. the investigators want to determine if mcc-ims diagnostic could be a faster alternative to conventional microbiological methods. the results of the mcc-ims analyses therefore will be compared with results of conventional microbiological methods.

in this clinical feasibility study it is to be investigated if mcc-ims analyses over clinical samples from ventilated critically ill patients could be a fast and secure alternative to conventional microbiological diagnostic methods in the identification of human pathogenic microbes in the setting of hospital-acquired pneumonia. therefore aspiration samples from intubated and ventilated critically ill patients, which are suspected to develop such an infection, will be collected and cultivated for a short period of time. the headspace over these cultures will be analyzed using mcc-ims - a technology that allows on time detection and identification of very small amounts of substances in complex and humid gas samples. conventional microbiological investigations, including maldi-tof, will be carried out parallel to the mcc-ims analyses.

Eligibility criteria:
inclusion criteria: * patient is at the hospital for more than 48 hours * patient is intubated and mechanically ventilated * clinical suspicion for an infection of the lower respiratory tract has been raised and decision for microbiological investigation of respiratory aspirate was made exclusion criteria: * patient is at the hospital for less than 48 hours * patient has been recruited for another clinical study * suspicion for an infection with a germ belonging to risk class 3 and 4 according to the german law (biostoffv and trba, e.g. mycobacterium tuberculosis)

Keywords: ion mobility spectrometry hospital-acquired pneumonia microbiological investigation intensive care
efficacy and safety of liuwei dihuang pill versus placebo in presbycusis with shen (kidney)-yin deficiency

Conditions: Presbycusis; Age-related Hearing Loss; Hearing Disorders and Deafness

Summary: the objective of this study is to examine the effects and safety of liuwei dihuang pill and placebo in presbycusis with shen (kidney)-yin deficiency.

there are no approved pharmacologic therapies for age-related hearing loss (arhl), also known as presbycusis. based on the syndrome differentiation in chinese medicine (cm) theory, the pathogenesis of presbycusis is related to the shen (kidney)-yin deficiency. liuwei dihuang pill (ldp) is effective and commonly prescribed for the treatment of shen-yin deficiency. the main purpose of this study is to try to demonstrate an improvement in phonetically balanced maximum (pbmax) after 1 years of treatment with the ldp versus the placebo. subjects will undergo a safety follow-up after the treatment period. safety and efficacy will be determined by looking at a number of assessments (physical examinations, blood sampling, hearing assessments, questionnaires, etc.).the amount of drug in the blood will also be measured. it is expected that around 120 people (at least 60 in each arm) with presbycusis with shen (kidney)-yin deficiency may take part in the study. the study participants will be recruited at around 6 sites in the shanghai, china.

Eligibility criteria:
inclusion criteria: 1. subjects must have a current diagnosis of presbyacusis with symmetrical hearing loss, defined as 15-db or less difference in pure tone average between ears at 0.5, 1, 2 and 4khz. the average hearing threshold loss level is mild or moderate (20 ≤ average hearing threshold \< 50 dbhl). 2. adult aged 65-75 years inclusive. 3. maximum speech recognition rate in quiet environment is equal to or over 60% with ability to communicate well. 4. subjects have no cognitive impairment with cdr score =0. 5. subjects must have a current diagnosis of shen (kidney)-yin deficiency. 6. subjects have read and voluntarily signed the informed consent form (icf) after all questions have been answered and prior to any study-mandated procedure. exclusion criteria: 1. subjects with sudden hearing loss or pure tone hearing fluctuation within the three months. 2. subjects with a history of serious mental illness. 3. subjects with severe cardiac insufficiency, malignant tumor or other serious systemic diseases. 4. subjects with conductive deafness, congenital deafness, hereditary deafness, inner ear immune and autoimmune inner ear diseases, auditory neuropathy, toxic deafness and noise deafness. 5. subjects with organic ear diseases, abnormal ear structure and symptomatic cerebral infarction. 6. subjects with dementia, neurosyphilis, hypothyroidism and depression. 7. subjects has previously participated in other clinical trial within the three months. 8. subjects with using hearing aids or devices. 9. other situations where the researcher thinks it is inappropriate to participate in this research.

Keywords: presbycusis age-related hearing loss liuwei dihuang pill
safety and efficacy study of omalizumab given prior to immunotherapy

Conditions: Asthma

Summary: in patients with at least moderate persistent allergic asthma controlled with inhaled steroids, omalizumab(administered per us product label), when compared to placebo, will provide the participants with significantly improved tolerability of specific allergen immunotherapy (allergy shots) administered per a cluster schedule(rapid build up method).

omalizumab is an fda approved anti-ige drug used to treat allergic asthma. this study is designed to give omalizumab 13 weeks prior to administering rapid build up of specific allergy shot, with an overlap of omalizumab and cluster therapy for 3 weeks. the cluster therapy will take 4 week to complete with maintenance dosage lasting an additional 6 weeks.

Eligibility criteria:
inclusion criteria: * clinical diagnosis and history of moderate persistent allergic asthma * body weight \>/= 20kg and \</= 150kg * total serum ige \>/= 30 and \</= 700iu/ml * on a stable asthma treatment including corticosteroids for the preceding 4 weeks * non smoker for at least 1 year prior to visit 1 exclusion criteria: * patients with severe asthma * history of immunotherapy to any allergen within the past 3 years * history of anaphylactic allergic reaction * upper respiratory tract infection

Keywords: allergic asthma immunotherapy
trial of kn026 in patients with her2-positive advanced malignant breast cancer and gastric cancer

Conditions: Breast Cancer; Gastric Cancer

Summary: this is a first-in-human (fih), open-label, phase 1 dose-escalation study of kn026 in subjects with her2 positive advanced breast and gastric cancer. the standard "3 + 3" design was used for dose escalation. there are 5 proposed dose levels which are 5, 10, 15, 20 and 30 mg/kg, but dosing interval may be adjusted during the study (such as qw, or q2w, or q3w) based on emerging data from this trial and/or from phase 1 trial of kn026 in other country. dose escalation will continue until the maximum tolerated dose (mtd) is reached or if mtd is not found, dose escalation will continue until the mad of 20 mg / kg is reached. dose expansion will carried out in 20 mg/kg q2w and 30 mg/kg q3w.


Eligibility criteria:
inclusion criteria: * male or female subject \>= 18 years and =\<75 years. * histologically or cytologically confirmed, locally advanced unresectable or metastatic breast cancer or gastric cancer. * ecog score 0 or 1. * life expectancy \>3 months. * according to the definition of recist1.1, the patient has at least one measurable lesion. * adequate organ function prior to start treatment with kn026. * able to understand, voluntarily participate and willing to sign the icf. * subjects (women of child-bearing potential and males with fertile female partner) must be willing to use viable contraception method. exclusion criteria: * accepted any other anti-tumor drug therapies within 4 weeks before fist dose. * accepted radiotherapy within 4 weeks before enrollment(subjects are eligible, which accepted palliative therapies within 2 weeks before the first dose of kn026 for osseous metastatic and all the aes recovered). * an anthracyclines antibiotic treatment, such as doxorubicin (adriamycin) was received exceeding 300 mg/m² within 90 days before first kn026 dosing, or other equivalent dose antharcyclines. * subjects are eligible with clinically controlled and stable neurologic function \>= 4 weeks, which is no evidence of cns disease progression; subjects with spinal cord compression and cancerous meningitis are not eligible. * pregnant or nursing females；or intend pregnancy within this study period or within 6 monthes after the end of this study. * has not recovered (ie, \>grade 1) from aes except alopecia and anemia. * history of immunodeficiency, including hiv positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation. * severe chronic and active infection, need to system antibiosis/antiviral treatment. * cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) are not well controlled, and need locally treatment or repeated drainage. -